Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis.

Détails

ID Serval
serval:BIB_0F4271488966
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis.
Périodique
Multiple sclerosis
Auteur⸱e⸱s
Putzki N., Knipp S., Ramczykowski T., Vago S., Germing U., Diener H.C., Limmroth V.
ISSN
1352-4585 (Print)
ISSN-L
1352-4585
Statut éditorial
Publié
Date de publication
06/2006
Peer-reviewed
Oui
Volume
12
Numéro
3
Pages
363-366
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Azathioprine (Aza) is a widely used immunosuppressive drug in multiple sclerosis (MS) treatment. Recently, the incidence of secondary myelodysplastic syndromes (sMDS) associated with a poor prognosis was found to be elevated in patients treated with Aza for non-malign disorders. Three hundred and seventeen MS patients were retrospectively analysed and complete blood counts were examined for those exposed to Aza. We identified one case of sMDS (cumulative dose 627 g) in a young patient and two further malignancies (cumulative doses 27 g and 54 g) in the Aza group (n = 81; 3.7%). In the non-Aza (n = 236) group, five malignancies (2.1%, P = 0.419) were identified. Including our patient, four cases of sMDS after long-term Aza therapy in MS have been reported so far. Cases suggest a time- and dose-dependent risk of sMDS in long-term therapy of MS with Aza. Long-term Aza therapy needs careful monitoring.
Mots-clé
Adolescent, Adult, Azathioprine/adverse effects, Female, Humans, Immunosuppressive Agents/adverse effects, Incidence, Male, Middle Aged, Multiple Sclerosis/drug therapy, Multiple Sclerosis/epidemiology, Myelodysplastic Syndromes/chemically induced, Myelodysplastic Syndromes/epidemiology, Prognosis, Retrospective Studies, Risk Factors
Pubmed
Web of science
Création de la notice
16/07/2019 12:24
Dernière modification de la notice
21/08/2019 5:36
Données d'usage